GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ectin Research AB (XSAT:ECTIN B) » Definitions » Common Stock

Ectin Research AB (XSAT:ECTIN B) Common Stock : kr1.59 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ectin Research AB Common Stock?

Ectin Research AB's quarterly common stock stayed the same from Sep. 2023 (kr1.59 Mil) to Dec. 2023 (kr1.59 Mil) and stayed the same from Dec. 2023 (kr1.59 Mil) to Mar. 2024 (kr1.59 Mil).

Ectin Research AB's annual common stock increased from Aug. 2020 (kr0.16 Mil) to Dec. 2022 (kr1.59 Mil) but then stayed the same from Dec. 2022 (kr1.59 Mil) to Dec. 2023 (kr1.59 Mil).


Ectin Research AB Common Stock Historical Data

The historical data trend for Ectin Research AB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ectin Research AB Common Stock Chart

Ectin Research AB Annual Data
Trend Aug19 Aug20 Dec22 Dec23
Common Stock
0.16 0.16 1.59 1.59

Ectin Research AB Quarterly Data
Aug19 Aug20 Mar21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.59 1.59 1.59 1.59 1.59

Ectin Research AB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Ectin Research AB (XSAT:ECTIN B) Business Description

Traded in Other Exchanges
N/A
Address
Pepparedsleden 1, Molndal, SWE, 431 83
Ectin Research AB is a pharmaceutical company developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 engages in the treatment of metastatic bladder cancer, and has also shown potential in other cancers such as breast, colorectal and prostate cancer cells.

Ectin Research AB (XSAT:ECTIN B) Headlines

No Headlines